Shire plc (SHPG) Tops Q4 EPS by 8c, Provides Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Shire (SHPG) is Not a Compelling Growth Story - Piper Jaffray
February 12, 2016 8:16 AM ESTPiper Jaffray analyst, David Amsellem, thinks Shire (NASDAQ: SHPG) does not represent a compelling growth story despite a number of regulatory catalysts in 2016. He reduced his PT to $175 from $219 and maintained his Neutral rating.
Shire reported 4Q15 non-GAAP EPS of $2.97 on revenues of $1.7B, versus the Street estimates of $2.87 and $1.7B, respectively. Vyvanse and Lialda were key bright spots, though these are also the products that likely have the shortest-lived durability in the combined SHPG/Baxalta portfolio (patent expiries in 2023 and... More
